This will be one of the largest public issues by a domestic drug manufacturer after the ₹6,480-crore IPO of Gland Pharma in 2020. The qualified institutional buyers (QIB) category was subscribed 49 times, while the non-institutional investors or high net-worth individuals’ portion was subscribed 3.8 times. However, the retail investor’s portion was under-subscribed at 92%.
AMFI Reshuffle: Five midcap stocks that may get upgraded to largecap
Nuvama Institutional Equities expects five midcap stocks, including Bosch, Zydus Lifesciences and Lodha Developers, to move into the largecap category in AMFI’s H1 CY27 reclassification.